Anticoagulation Therapy in Atrial Fibrillation: Comparing DOACs and Warfarin

Anticoagulation therapy plays a pivotal role in the management of atrial fibrillation (AF), aiming to prevent thromboembolic events such as stroke. Direct oral anticoagulants (DOACs) have increasingly replaced warfarin as the treatment of choice for many AF patients due to their favorable pharmacological properties, including predictable pharmacokinetics, fixed dosing, and minimal need for monitoring. This review compares the efficacy, safety, and patient outcomes associated with DOACs (apixaban, rivaroxaban, dabigatran, and edoxaban) and warfarin in the context of AF management. We discuss key clinical trials that have demonstrated the non-inferiority or superiority of DOACs compared to warfarin in terms of stroke prevention and major bleeding risk. However, despite the advantages of DOACs, their high cost, limited reversal options, and drug interactions remain concerns in clinical practice. Warfarin, while effective, requires frequent monitoring of the international normalized ratio (INR) and has a higher risk of bleeding, but it remains a cost-effective option in certain populations. The review also explores the impact of renal function, age, and comorbid conditions on the choice of anticoagulant therapy. Lastly, we examine ongoing research into novel anticoagulants and the development of reversal agents for DOACs. Personalized treatment decisions based on patient characteristics, preferences, and clinical guidelines are essential for optimizing anticoagulation therapy in AF.